Quick Answer
NeuroSense Therapeutics Ltd. reported Cash and Equivalents of $166.0 thousand for fiscal year 2025.
NeuroSense Therapeutics Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $166.0K | -95.1% |
| 2024 | $3.38M | +28.0% |
| 2023 | $2.64M | — |
- NeuroSense Therapeutics Ltd. showed a decrease of -95.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, NeuroSense Therapeutics Ltd.’s cash and equivalents has declined by 93.7% (from $2.64 million to $166.0 thousand).
- The most recent figure is from NeuroSense Therapeutics Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: